Next Article in Journal
Choline Supplementation Normalizes Fetal Adiposity and Reduces Lipogenic Gene Expression in a Mouse Model of Maternal Obesity
Next Article in Special Issue
Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer’s Disease
Previous Article in Journal
Applying a Consumer Behavior Lens to Salt Reduction Initiatives
Previous Article in Special Issue
Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Nutrients 2017, 9(8), 897;

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance

Spinal Ospedale Cannizzaro, University of Catania, 95100 Catania, Italy
Department of Internal Medicine and Systemic Diseases, University of Catania, 95123 Catania, Italy
Research Center “The Great Senescence”, University of Catania, 95100 Catania, Italy
Neurovisual Science Technology (NEST), SpinLab, 95100 Catania, Italy
Department “G.F. Ingrassia”, Section of Neurosciences, University of Catania, 95123 Catania, Italy
Department of Biomedical Science, University of Sassari, 07100 Sassari, Italy
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Author to whom correspondence should be addressed.
Received: 24 July 2017 / Revised: 7 August 2017 / Accepted: 15 August 2017 / Published: 18 August 2017
(This article belongs to the Special Issue Effects of Resveratrol Supplementation on Human Health and Disease)
Full-Text   |   PDF [910 KB, uploaded 18 August 2017]   |  


Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV. View Full-Text
Keywords: resveratrol; interferons; ribavirin; hepatitis C; sleep disorders resveratrol; interferons; ribavirin; hepatitis C; sleep disorders

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pennisi, M.; Bertino, G.; Gagliano, C.; Malaguarnera, M.; Bella, R.; Borzì, A.M.; Madeddu, R.; Drago, F.; Malaguarnera, G. Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients 2017, 9, 897.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top